Effect of Electroacupuncture on Central Obesity and Fatty Liver in Postmenopausal Women
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Medical treatment, Hypocaloric diet, Electroacupuncture.
- Who it may be relevant to
- Registry conditions: Postmenopausal Women. Basic parameters: 50 years — 60 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effect of Electroacupuncture on Central Obesity and Fatty Liver in Postmenopausal Women: A Randomized Controlled Trial
Overview
The aim of this study is to determine the effect of electroacupuncture on central obesity and fatty liver in postmenopausal women.
Detailed description
Post menopause is the time after you've been without a menstrual period for 12 months. It lasts for the rest of your life. During this stage, menopausal symptoms, such as hot flashes, get milder or go away.
Electro-acupuncture has a major advantage that it's the margin of error in needle placement for electro-acupuncture is greater than for manual therapy and therefore a less accurate placement is required, as the current spreads and may reach a nerve several millimeters away.
In electro-acupuncture, the therapist inserts the acupuncture needles in acupuncture points and electric current is connected to the body through the acupuncture needles.
Electro-acupuncture treatment helps in decreasing blood lipids in patients with fatty liver disease and plays a significant role in improving the immunity system in patients with hepatitis in addition to improving their clinical symptoms. Previous clinical studies in China indicated that electro-acupuncture able to decrease total cholesterol (TC), triglycerides (TG), low-density lipoproteins (LDL), and elevate high-density lipoproteins (HDL) in patients suffering from dyslipidemia.
Interventions
- Drug Medical treatment
All women in both groups will adhere to the same medication (orlistat) as prescribed by the gynecologist for 12 weeks. - Other Hypocaloric diet
All women in both groups will be instructed to follow the same hypocaloric diet, as prescribed by a certified nutrition specialist, with a daily caloric intake of 1,200 kcal for a duration of 12 weeks. - Other Electroacupuncture
Women in the experimental group only will undergo electroacupuncture three times per week for 12 weeks. Treatment will be delivered in the supine position using sterile needles inserted at eight standardized acupoints associated with central obesity and weight regulation, with insertion depths of 10-25 mm. Low-frequency electrical stimulation (2 Hz, 0.5 ms) will be applied to the abdominal region for 30 minutes per session.
Primary outcome measures
- Body Mass Index (BMI) [Time frame: 12 weeks]
- Waist Circumference [Time frame: 12 weeks]
- Hip Circumference [Time frame: 12 weeks]
- Waist-to-Hip Ratio (WHR) [Time frame: 12 weeks]
- Serum Glutamic-Oxaloacetic Transaminase (SGOT / AST) [Time frame: 12 weeks]
- Serum Glutamic-Pyruvic Transaminase (SGPT / ALT) [Time frame: 12 weeks]
Secondary outcome measures (4)
- Total Cholesterol (TC) [Time frame: 12 weeks]
- Triglycerides (TG) [Time frame: 12 weeks]
- Low-Density Lipoprotein Cholesterol (LDL) [Time frame: 12 weeks]
- High-Density Lipoprotein Cholesterol (HDL) [Time frame: 12 weeks]
Eligibility criteria
Inclusion criteria
- Their ages will be ranged between 50 and 60 years old.
- Their body mass index will be ranged from 30-40 kg/m2.
- SGOT more 40 U/L.
- SGPT more 40 U/L.
- Waist/Hip Ratio more 1 cm.
- Triglyceride more 150 mg/dl.
- Cholesterol more 200 mg/dl.
- LDL more 100 mg/dl.
- HDL less 40 mg/dl.
Exclusion criteria
- Cancer.
- Concomitant cardiovascular disorders.
- Respiratory, renal and liver dysfunction.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Aga Central Hospital — Aga
Identifiers
NCT: NCT07437001 · P.T.REC/012/005973